BioCentury
ARTICLE | Financial News

Trimeris down on Fuzeon sales

July 23, 2003 7:00 AM UTC

TRMS slipped $2.45 to $46.58 on 2 million shares on Wednesday after posting lighter than expected initial sales of Fuzeon enfuvirtide for HIV. Second quarter sales of the product - which was approved ...